New study expands immunotherapy eligibility for colorectal and endometrial cancer patients

A new study shows thousands more patients diagnosed with colorectal and endometrial cancers could benefit from immunotherapy than are currently offered it.

What’s next for Cassava Sciences, and Cartesian Therapeutics has a novel excuse for dodgy data

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Taking

July 3, 2024

vTv Therapeutics’ diabetes drug program hit with clinical hold from FDA

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 30, 2024

Adalimumab biosimilar by Biocon for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval

Adalimumab biosimilar is under clinical development by Biocon and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris).

March 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.